VAXSIA BIOMEDICAL INC.
Update：2026/09/15
Industries
Main Industry
Biotechnology
Main Product/Service
The VADEX technology platform is a self-adjuvanting protein nanoparticle platform. Its constituent units are formed by fusing a specific-sequence amphiphilic peptide with a superfolder green fluorescent protein. Although this amphiphilic peptide is only 19 amino acids long, it possesses both adjuvant functionality and nanoparticle self-assembly capability. Foreign proteins can be directly fused onto the nanoparticles or linked to the nanoparticles through irreversible complementary conjugation. Because nanoparticles formed using VADEX technology can induce long-lasting antibody responses without the need for external adjuvants, vaccines developed based on VADEX technology can withstand high temperatures of up to 40°C for more than two months. With this technology, children around the world, whether living in deserts or tropical rainforests, will be able to grow up healthy in the future.
(The content above was translated by AI.)
(The content above was translated by AI.)
Founded Year
2010
Unified Business No.
29171100
Status
Active
Number of Employees
2
Total Paid-in
Capital
15,750,000 (NT$)
Location of Company
Taiwan
, Taipei City
Information such as company name, company status, responsible person, year of establishment, paid-in capital, and registered address is sourced from the Commercial and Industrial Registration Office of the Ministry of Economic Affairs; listing status includes emerging stock, M&A, and IPO; overseas development is provided by the startup itself.
Notice: This data is compiled from public sources for reference only. We have no direct affiliation with the company and are not their contact person.
Exclusive content for members
Members-only content. Please log in to access.
About the Company
Huaxiya Biomedical Co., Ltd. was founded in July 2010. The company was originally named Meikang Biotechnology Co., Ltd. To make it easier to identify due to its similarity to another company's name, it was renamed Huaxiya Biomedical Co., Ltd. in September 2013. The company's R&D department began conducting preliminary research in the open laboratory of the NanKang Biotech Incubation Center as a Category 3 member in March 2013, passed the admission application review of the NanKang Biotech Incubation Center in November 2013, and officially moved into the NanKang Biotech Incubation Center in March 2014. Huaxiya Biomedical's vision is to make vaccines accessible to every corner of the world. VADEX is a self-adjuvanting, thermostable protein nanoparticle platform technology that can effectively express peptides or proteins to become vaccines or other functional biologics.
(The content above was translated by AI.)
(The content above was translated by AI.)
